Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer
This study was designed to evaluate the efficacy and safety of irinotecan in combination with carboplatin in previously untreated, extensive-disease small-cell lung cancer (ED-SCLC). Patients with histologically or cytologically confirmed ED-SCLC received irinotecan (60 mg/m 2 on days 1, 8, and 15)...
Saved in:
Published in | Medical oncology (Northwood, London, England) Vol. 28; no. 1; pp. 342 - 350 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Boston
Springer US
01.03.2011
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | This study was designed to evaluate the efficacy and safety of irinotecan in combination with carboplatin in previously untreated, extensive-disease small-cell lung cancer (ED-SCLC). Patients with histologically or cytologically confirmed ED-SCLC received irinotecan (60 mg/m
2
on days 1, 8, and 15) plus carboplatin (AUC 5 on day 1) every 4 weeks. Treatment was repeated until disease progression, unacceptable toxicity, or up to 6 cycles. Forty-four patients were enrolled. In an intent-to-treat analysis, the overall response rate (RR) was 75% (8 complete responses and 25 partial responses). The median progression-free (PFS) and overall survival (OS) were 5.6 and 8.7 months, respectively. The principle toxicities were neutropenia and diarrhea. Grade 3–4 neutropenia occurred in 30% of the patients and 7% of patients presented with febrile neutropenia. Grade 3–4 diarrhea occurred in 21% of the patients. A subgroup consisting of patients ≥65 years of age had outcomes similar to the younger group <65 years of age. The objective RR was 72% in the patients <65 years of age and 77% in the patients ≥65 years of age (
P
= .738). The median PFS and OS (<65 years vs. ≥65 years) were 5.3 vs. 5.6 months (
P
= .835) and 9.0 vs. 8.7 months (
P
= .648), respectively. The combination of irinotecan and carboplatin is active and tolerable in patients with ED-SCLC. This regimen could be considered as a treatment option for patients of advanced age. |
---|---|
AbstractList | This study was designed to evaluate the efficacy and safety of irinotecan in combination with carboplatin in previously untreated, extensive-disease small-cell lung cancer (ED-SCLC). Patients with histologically or cytologically confirmed ED-SCLC received irinotecan (60 mg/m(2) on days 1, 8, and 15) plus carboplatin (AUC 5 on day 1) every 4 weeks. Treatment was repeated until disease progression, unacceptable toxicity, or up to 6 cycles. Forty-four patients were enrolled. In an intent-to-treat analysis, the overall response rate (RR) was 75% (8 complete responses and 25 partial responses). The median progression-free (PFS) and overall survival (OS) were 5.6 and 8.7 months, respectively. The principle toxicities were neutropenia and diarrhea. Grade 3-4 neutropenia occurred in 30% of the patients and 7% of patients presented with febrile neutropenia. Grade 3-4 diarrhea occurred in 21% of the patients. A subgroup consisting of patients ≥ 65 years of age had outcomes similar to the younger group <65 years of age. The objective RR was 72% in the patients <65 years of age and 77% in the patients ≥ 65 years of age (P = .738). The median PFS and OS (<65 years vs. ≥ 65 years) were 5.3 vs. 5.6 months (P = .835) and 9.0 vs. 8.7 months (P = .648), respectively. The combination of irinotecan and carboplatin is active and tolerable in patients with ED-SCLC. This regimen could be considered as a treatment option for patients of advanced age. This study was designed to evaluate the efficacy and safety of irinotecan in combination with carboplatin in previously untreated, extensive-disease small-cell lung cancer (ED-SCLC). Patients with histologically or cytologically confirmed ED-SCLC received irinotecan (60 mg/m 2 on days 1, 8, and 15) plus carboplatin (AUC 5 on day 1) every 4 weeks. Treatment was repeated until disease progression, unacceptable toxicity, or up to 6 cycles. Forty-four patients were enrolled. In an intent-to-treat analysis, the overall response rate (RR) was 75% (8 complete responses and 25 partial responses). The median progression-free (PFS) and overall survival (OS) were 5.6 and 8.7 months, respectively. The principle toxicities were neutropenia and diarrhea. Grade 3–4 neutropenia occurred in 30% of the patients and 7% of patients presented with febrile neutropenia. Grade 3–4 diarrhea occurred in 21% of the patients. A subgroup consisting of patients ≥65 years of age had outcomes similar to the younger group <65 years of age. The objective RR was 72% in the patients <65 years of age and 77% in the patients ≥65 years of age ( P = .738). The median PFS and OS (<65 years vs. ≥65 years) were 5.3 vs. 5.6 months ( P = .835) and 9.0 vs. 8.7 months ( P = .648), respectively. The combination of irinotecan and carboplatin is active and tolerable in patients with ED-SCLC. This regimen could be considered as a treatment option for patients of advanced age. This study was designed to evaluate the efficacy and safety of irinotecan in combination with carboplatin in previously untreated, extensive-disease small-cell lung cancer (ED-SCLC). Patients with histologically or cytologically confirmed ED-SCLC received irinotecan (60 mg/m^sup 2^ on days 1, 8, and 15) plus carboplatin (AUC 5 on day 1) every 4 weeks. Treatment was repeated until disease progression, unacceptable toxicity, or up to 6 cycles. Forty-four patients were enrolled. In an intent-to-treat analysis, the overall response rate (RR) was 75% (8 complete responses and 25 partial responses). The median progression-free (PFS) and overall survival (OS) were 5.6 and 8.7 months, respectively. The principle toxicities were neutropenia and diarrhea. Grade 3-4 neutropenia occurred in 30% of the patients and 7% of patients presented with febrile neutropenia. Grade 3-4 diarrhea occurred in 21% of the patients. A subgroup consisting of patients ≥65 years of age had outcomes similar to the younger group <65 years of age. The objective RR was 72% in the patients <65 years of age and 77% in the patients ≥65 years of age (P = .738). The median PFS and OS (<65 years vs. ≥65 years) were 5.3 vs. 5.6 months (P = .835) and 9.0 vs. 8.7 months (P = .648), respectively. The combination of irinotecan and carboplatin is active and tolerable in patients with ED-SCLC. This regimen could be considered as a treatment option for patients of advanced age.[PUBLICATION ABSTRACT] |
Author | Park, Jeong Woong Jung, Sung Hwan Shin, Dong Bok Cho, Eun Kyung Kim, Young Saing Sym, Sun Jin Park, Jinny Kyung, Sun Young Park, Se Hoon Lee, Jae Hoon Lee, Sang Pyo |
Author_xml | – sequence: 1 givenname: Young Saing surname: Kim fullname: Kim, Young Saing organization: Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital – sequence: 2 givenname: Se Hoon surname: Park fullname: Park, Se Hoon organization: Division of Hematology and Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine – sequence: 3 givenname: Sun Young surname: Kyung fullname: Kyung, Sun Young organization: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Gachon University Gil Hospital – sequence: 4 givenname: Sun Jin surname: Sym fullname: Sym, Sun Jin organization: Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital – sequence: 5 givenname: Sang Pyo surname: Lee fullname: Lee, Sang Pyo organization: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Gachon University Gil Hospital – sequence: 6 givenname: Jeong Woong surname: Park fullname: Park, Jeong Woong organization: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Gachon University Gil Hospital – sequence: 7 givenname: Sung Hwan surname: Jung fullname: Jung, Sung Hwan organization: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Gachon University Gil Hospital – sequence: 8 givenname: Jinny surname: Park fullname: Park, Jinny organization: Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital – sequence: 9 givenname: Eun Kyung surname: Cho fullname: Cho, Eun Kyung email: ekcho@gilhospital.com, zoomboom@hanmail.net organization: Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital – sequence: 10 givenname: Jae Hoon surname: Lee fullname: Lee, Jae Hoon organization: Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital – sequence: 11 givenname: Dong Bok surname: Shin fullname: Shin, Dong Bok organization: Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20198458$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kE1LxDAQhoOsuK76A7xI8eIpOkk2aXMU8QsELy54C9l0ula6aU1av369WXZVEISBGcjzvjN5J2TkW4-EHDI4ZQD5WWQcBKfAgOqpFPRzi-wyKTVlgj2O0ixkTkEqGJNJjM8AnEmud8iYA9PFVBa7ZHYbat_26KzPumaImbNh3naN7WufperSgL6P2VvdP2X43qOP9SvSso5oI2ZxaZuGOmyarBn8Ism9w7BPtivbRDzY9D0yu7p8uLihd_fXtxfnd9SJHHpagSut5lXJGNdzPUfOlbMIGllZqKkr8inaUmClXMW1tqySKoeSaaVFlT4g9sjJ2rcL7cuAsTfLOq6OsR7bIZpCCq1VAZDI4z_kczsEn45bQarQUqsEsTXkQhtjwMp0oV7a8GEYmFXiZp24SYmbVeLmM2mONsbDfInlj-I74gTwNRDTk19g-N38v-sXW_mOyQ |
CODEN | MONCEZ |
CitedBy_id | crossref_primary_10_1002_jbm_b_31858 crossref_primary_10_1007_s11101_015_9397_1 crossref_primary_10_6058_jlc_2011_10_1_49 crossref_primary_10_1310_hpj4907_603 crossref_primary_10_1016_j_resinv_2015_02_006 crossref_primary_10_1007_s00280_011_1689_6 |
Cites_doi | 10.1016/j.lungcan.2006.08.014 10.1016/0002-9343(69)90071-0 10.1200/JCO.2005.04.4859 10.1200/JCO.2007.15.7545 10.1016/j.lungcan.2006.05.004 10.1038/sj.bjc.6603079 10.1200/JCO.2005.81.908 10.1016/j.hoc.2003.12.008 10.1097/JTO.0b013e31814617b7 10.1111/j.1447-0594.2009.00525.x 10.1093/annonc/mdj137 10.1016/S0169-5002(00)00127-6 10.1016/0197-2456(89)90015-9 10.1200/JCO.2005.03.3332 10.1056/NEJMoa003034 10.1016/S1040-8428(03)00118-5 10.1200/JCO.2008.20.2127 10.1002/(SICI)1097-0142(19980601)82:11<2166::AID-CNCR11>3.0.CO;2-S 10.1038/ncponc1324 10.1159/000227087 10.1159/000180580 10.1200/JCO.2005.09.071 10.1097/JTO.0b013e3181bbc540 10.1200/JCO.2005.04.8595 10.1200/JCO.2008.20.1061 10.1093/jnci/83.12.855 10.1016/S0889-8588(05)70284-7 10.1200/JCO.2001.19.18.3801 10.1200/JCO.1994.12.10.2022 10.1093/oxfordjournals.annonc.a058931 10.1016/S1556-0864(15)31579-3 10.1200/JCO.1987.5.10.1574 10.1093/jnci/94.3.173 10.1200/JCO.1996.14.1.135 10.1200/jco.2009.27.15_suppl.8029 10.1200/JCO.1992.10.8.1225 10.1200/JCO.1989.7.11.1748 10.1200/JCO.1992.10.2.282 10.1200/JCO.1999.17.9.2710 |
ContentType | Journal Article |
Copyright | Springer Science+Business Media, LLC 2010 Springer Science+Business Media, LLC 2011 |
Copyright_xml | – notice: Springer Science+Business Media, LLC 2010 – notice: Springer Science+Business Media, LLC 2011 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1007/s12032-010-9453-z |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE ProQuest One Academic Eastern Edition |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1559-131X |
EndPage | 350 |
ExternalDocumentID | 2275807681 10_1007_s12032_010_9453_z 20198458 |
Genre | Clinical Trial, Phase II Journal Article Feature |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 2.D 203 28- 29M 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 3V. 4.4 406 408 40E 53G 5GY 5RE 5VS 6NX 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAWTL AAYFA AAYIU AAYQN AAYTO ABDZT ABECU ABFGW ABFTV ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABUWG ABWNU ABXPI ACBMV ACBRV ACBYP ACCUX ACGFS ACHSB ACHVE ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEEQQ AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFEXP AFKRA AFLOW AFNRJ AFQWF AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI HF~ HG6 HMCUK HMJXF HRMNR HVGLF HZ~ IJ- IKXTQ IMOTQ IWAJR IXD I~X I~Z J-C J0Z JBSCW JZLTJ KOV LLZTM M1P M4Y MA- N2Q N9A NDZJH NF0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OVD P19 P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 PZZ Q2X QOK QOR QOS R89 R9I RHV RIG RNI ROL RPX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 YLTOR Z7U Z82 Z83 Z87 Z8O Z8V Z91 ZMTXR ZOVNA ZXP ~A9 ~EX AACDK AAEOY AAJBT AASML ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF ALIPV CGR CUY CVF ECM EIF H13 NPM SJYHP AAYXX CITATION 7XB 8FK K9. PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-c370t-f0cda92fd1129b9be226cae09e1d864c874ead3ef6cf299a1f5670d19693f9843 |
IEDL.DBID | U2A |
ISSN | 1357-0560 |
IngestDate | Fri Aug 16 08:35:57 EDT 2024 Fri Sep 13 08:35:03 EDT 2024 Thu Sep 12 18:03:54 EDT 2024 Sat Sep 28 07:47:11 EDT 2024 Sat Dec 16 12:02:39 EST 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Carboplatin Irinotecan Chemotherapy Small-cell lung cancer |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c370t-f0cda92fd1129b9be226cae09e1d864c874ead3ef6cf299a1f5670d19693f9843 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 20198458 |
PQID | 853689596 |
PQPubID | 30753 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_853996800 proquest_journals_853689596 crossref_primary_10_1007_s12032_010_9453_z pubmed_primary_20198458 springer_journals_10_1007_s12032_010_9453_z |
PublicationCentury | 2000 |
PublicationDate | 2011-03-01 |
PublicationDateYYYYMMDD | 2011-03-01 |
PublicationDate_xml | – month: 03 year: 2011 text: 2011-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Boston |
PublicationPlace_xml | – name: Boston – name: United States – name: Middlesex |
PublicationTitle | Medical oncology (Northwood, London, England) |
PublicationTitleAbbrev | Med Oncol |
PublicationTitleAlternate | Med Oncol |
PublicationYear | 2011 |
Publisher | Springer US Springer Nature B.V |
Publisher_xml | – name: Springer US – name: Springer Nature B.V |
References | Govindan (CR1) 2006; 24 Rowland (CR3) 1996; 14 Mascaux (CR19) 2000; 30 Noda (CR9) 2002; 346 Rothenberg, Meropol, Poplin, Van Cutsem, Wadler (CR42) 2001; 19 Schmittel (CR37) 2006; 17 Kudoh (CR8) 1998; 16 Masuda (CR7) 1992; 10 Murray, Turrisi (CR2) 2006; 1 Johnson, Janne (CR17) 2004; 18 Schmittel (CR39) 2009; 27 Dimitroulis (CR26) 2008; 20 Ihde (CR5) 1994; 12 Li, Chen, Dai, Li, Bao (CR34) 2009; 9 Sohn (CR31) 2006; 54 Chen (CR36) 2009; 27 DeVore (CR29) 1999; 17 Therasse (CR14) 2000; 92 Cockcroft, Gault (CR13) 1976; 16 Spigel (CR40) 2007; 2 Langer (CR33) 2002; 94 Skarlos (CR11) 1994; 5 Niell (CR25) 2005; 23 Okamoto, Nagatomo, Kunitoh, Kunikane, Watanabe (CR28) 1998; 82 Calvert (CR12) 1989; 7 Spigel (CR41) 2009; 4 Green, Humphrey, Close, Patno (CR16) 1969; 46 Rothenberg (CR6) 1996; 23 Lara (CR23) 2009; 27 Okamoto (CR35) 2006; 53 Hanna (CR22) 2006; 24 Simon (CR15) 1989; 10 Simon, Argiris, Murren (CR18) 2004; 49 Bishop (CR10) 1987; 5 Eckardt (CR27) 2006; 24 Kinoshita (CR30) 2006; 94 Balducci, Corcoran (CR32) 2000; 14 Hermes (CR38) 2008; 26 Shah, Ilson, Kelsen (CR43) 2005; 23 Schmittel, Keilholz (CR21) 2009; 6 Miyamoto (CR24) 1992; 49 Fukuoka (CR20) 1991; 83 Roth (CR4) 1992; 10 1321891 - J Clin Oncol. 1992 Aug;10 (8):1225-9 5791000 - Am J Med. 1969 Apr;46(4):516-25 17409868 - J Thorac Oncol. 2006 Mar;1(3):270-8 9508192 - J Clin Oncol. 1998 Mar;16(3):1068-74 7931470 - J Clin Oncol. 1994 Oct;12(10):2022-34 16622467 - Br J Cancer. 2006 May 8;94(9):1267-71 2702835 - Control Clin Trials. 1989 Mar;10(1):1-10 16781005 - Lung Cancer. 2006 Aug;53(2):197-203 9610696 - Cancer. 1998 Jun 1;82(11):2166-72 17008692 - J Clin Oncol. 2006 Oct 1;24(28):4539-44 15795413 - J Clin Oncol. 2005 Apr 10;23 (11):2574-6 17011068 - Lung Cancer. 2006 Dec;54(3):365-70 2681557 - J Clin Oncol. 1989 Nov;7(11):1748-56 2821197 - J Clin Oncol. 1987 Oct;5(10):1574-8 15012973 - Crit Rev Oncol Hematol. 2004 Feb;49(2):119-33 16423848 - Ann Oncol. 2006 Apr;17 (4):663-7 11008007 - Lung Cancer. 2000 Oct;30(1):23-36 15923572 - J Clin Oncol. 2005 Jun 1;23(16):3752-9 7993835 - Ann Oncol. 1994 Sep;5(7):601-7 8558188 - J Clin Oncol. 1996 Jan;14(1):135-41 15094173 - Hematol Oncol Clin North Am. 2004 Apr;18(2):309-22 11784874 - N Engl J Med. 2002 Jan 10;346(2):85-91 1244564 - Nephron. 1976;16(1):31-41 8633249 - Semin Oncol. 1996 Feb;23 (1 Suppl 3):21-6 11559717 - J Clin Oncol. 2001 Sep 15;19(18):3801-7 16648504 - J Clin Oncol. 2006 May 1;24(13):2044-51 10680078 - Hematol Oncol Clin North Am. 2000 Feb;14(1):193-212, x-xi 10561345 - J Clin Oncol. 1999 Sep;17 (9):2710-20 19875975 - J Thorac Oncol. 2009 Dec;4(12 ):1555-60 10655437 - J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 1310103 - J Clin Oncol. 1992 Feb;10(2):282-91 19349543 - J Clin Oncol. 2009 May 20;27(15):2530-5 1334539 - Oncology. 1992;49(6):431-5 16648503 - J Clin Oncol. 2006 May 1;24(13):2038-43 11830607 - J Natl Cancer Inst. 2002 Feb 6;94(3):173-81 19204194 - J Clin Oncol. 2009 Mar 20;27(9):1401-4 19740361 - Geriatr Gerontol Int. 2009 Jun;9(2):172-82 19153568 - Nat Clin Pract Oncol. 2009 Mar;6(3):134-5 1648142 - J Natl Cancer Inst. 1991 Jun 19;83(12):855-61 18779613 - J Clin Oncol. 2008 Sep 10;26(26):4261-7 18813830 - Oncol Rep. 2008 Oct;20(4):879-84 17805064 - J Thorac Oncol. 2007 Sep;2(9):854-61 JR Eckardt (9453_CR27) 2006; 24 HB Niell (9453_CR25) 2005; 23 RF DeVore (9453_CR29) 1999; 17 A Schmittel (9453_CR37) 2006; 17 K Noda (9453_CR9) 2002; 346 RA Green (9453_CR16) 1969; 46 DR Spigel (9453_CR40) 2007; 2 KM Rowland Jr (9453_CR3) 1996; 14 DW Cockcroft (9453_CR13) 1976; 16 DC Ihde (9453_CR5) 1994; 12 BJ Roth (9453_CR4) 1992; 10 J Li (9453_CR34) 2009; 9 DV Skarlos (9453_CR11) 1994; 5 A Kinoshita (9453_CR30) 2006; 94 MA Shah (9453_CR43) 2005; 23 L Balducci (9453_CR32) 2000; 14 CJ Langer (9453_CR33) 2002; 94 R Simon (9453_CR15) 1989; 10 H Okamoto (9453_CR28) 1998; 82 DR Spigel (9453_CR41) 2009; 4 BE Johnson (9453_CR17) 2004; 18 R Govindan (9453_CR1) 2006; 24 N Hanna (9453_CR22) 2006; 24 JF Bishop (9453_CR10) 1987; 5 G Chen (9453_CR36) 2009; 27 ML Rothenberg (9453_CR42) 2001; 19 J Dimitroulis (9453_CR26) 2008; 20 A Schmittel (9453_CR39) 2009; 27 S Kudoh (9453_CR8) 1998; 16 AH Calvert (9453_CR12) 1989; 7 JH Sohn (9453_CR31) 2006; 54 ML Rothenberg (9453_CR6) 1996; 23 N Murray (9453_CR2) 2006; 1 H Okamoto (9453_CR35) 2006; 53 P Therasse (9453_CR14) 2000; 92 N Masuda (9453_CR7) 1992; 10 A Hermes (9453_CR38) 2008; 26 C Mascaux (9453_CR19) 2000; 30 M Fukuoka (9453_CR20) 1991; 83 A Schmittel (9453_CR21) 2009; 6 PN Lara Jr (9453_CR23) 2009; 27 H Miyamoto (9453_CR24) 1992; 49 M Simon (9453_CR18) 2004; 49 |
References_xml | – volume: 10 start-page: 1225 year: 1992 end-page: 1229 ident: CR7 article-title: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer publication-title: J Clin Oncol contributor: fullname: Masuda – volume: 54 start-page: 365 year: 2006 end-page: 370 ident: CR31 article-title: A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer publication-title: Lung Cancer doi: 10.1016/j.lungcan.2006.08.014 contributor: fullname: Sohn – volume: 46 start-page: 516 year: 1969 end-page: 525 ident: CR16 article-title: Alkylating agents in bronchogenic carcinoma publication-title: Am J Med doi: 10.1016/0002-9343(69)90071-0 contributor: fullname: Patno – volume: 17 start-page: 2710 year: 1999 end-page: 2720 ident: CR29 article-title: Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer publication-title: J Clin Oncol contributor: fullname: DeVore – volume: 24 start-page: 4539 year: 2006 end-page: 4544 ident: CR1 article-title: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.4859 contributor: fullname: Govindan – volume: 26 start-page: 4261 year: 2008 end-page: 4267 ident: CR38 article-title: Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.7545 contributor: fullname: Hermes – volume: 27 start-page: abstr 8029 year: 2009 ident: CR39 article-title: Irinotecan plus carboplatin versus etoposide plus carboplatin in extensive disease small cell lung cancer: Results of the German randomized phase III trial publication-title: J Clin Oncol contributor: fullname: Schmittel – volume: 5 start-page: 601 year: 1994 end-page: 607 ident: CR11 article-title: Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study publication-title: Ann Oncol contributor: fullname: Skarlos – volume: 53 start-page: 197 year: 2006 end-page: 203 ident: CR35 article-title: A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer publication-title: Lung Cancer doi: 10.1016/j.lungcan.2006.05.004 contributor: fullname: Okamoto – volume: 94 start-page: 173 year: 2002 end-page: 181 ident: CR33 article-title: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial publication-title: J Natl Cancer Inst contributor: fullname: Langer – volume: 94 start-page: 1267 year: 2006 end-page: 1271 ident: CR30 article-title: Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603079 contributor: fullname: Kinoshita – volume: 19 start-page: 3801 year: 2001 end-page: 3807 ident: CR42 article-title: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel publication-title: J Clin Oncol contributor: fullname: Wadler – volume: 23 start-page: 2574 year: 2005 end-page: 2576 ident: CR43 article-title: Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy publication-title: J Clin Oncol doi: 10.1200/JCO.2005.81.908 contributor: fullname: Kelsen – volume: 18 start-page: 309 year: 2004 end-page: 322 ident: CR17 article-title: Basic treatment considerations using chemotherapy for patients with small cell lung cancer publication-title: Hematol Oncol Clin North Am doi: 10.1016/j.hoc.2003.12.008 contributor: fullname: Janne – volume: 2 start-page: 854 year: 2007 end-page: 861 ident: CR40 article-title: Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e31814617b7 contributor: fullname: Spigel – volume: 92 start-page: 205 year: 2000 end-page: 216 ident: CR14 article-title: New guidelines to evaluate the response to treatment in solid tumors publication-title: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst contributor: fullname: Therasse – volume: 9 start-page: 172 year: 2009 end-page: 182 ident: CR34 article-title: Outcome and treatment in elderly patients with small cell lung cancer: a retrospective study publication-title: Geriatr Gerontol Int doi: 10.1111/j.1447-0594.2009.00525.x contributor: fullname: Bao – volume: 17 start-page: 663 year: 2006 end-page: 667 ident: CR37 article-title: A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdj137 contributor: fullname: Schmittel – volume: 14 start-page: 135 year: 1996 end-page: 141 ident: CR3 article-title: Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study publication-title: J Clin Oncol contributor: fullname: Rowland – volume: 30 start-page: 23 year: 2000 end-page: 36 ident: CR19 article-title: A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis publication-title: Lung Cancer doi: 10.1016/S0169-5002(00)00127-6 contributor: fullname: Mascaux – volume: 20 start-page: 879 year: 2008 end-page: 884 ident: CR26 article-title: Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study publication-title: Oncol Rep contributor: fullname: Dimitroulis – volume: 1 start-page: 270 year: 2006 end-page: 278 ident: CR2 article-title: A review of first-line treatment for small-cell lung cancer publication-title: J Thorac Oncol contributor: fullname: Turrisi – volume: 10 start-page: 282 year: 1992 end-page: 291 ident: CR4 article-title: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group publication-title: J Clin Oncol contributor: fullname: Roth – volume: 10 start-page: 1 year: 1989 end-page: 10 ident: CR15 article-title: Optimal two-stage designs for phase II clinical trials publication-title: Control Clin Trials doi: 10.1016/0197-2456(89)90015-9 contributor: fullname: Simon – volume: 24 start-page: 2044 year: 2006 end-page: 2051 ident: CR27 article-title: Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.03.3332 contributor: fullname: Eckardt – volume: 12 start-page: 2022 year: 1994 end-page: 2034 ident: CR5 article-title: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer publication-title: J Clin Oncol contributor: fullname: Ihde – volume: 346 start-page: 85 year: 2002 end-page: 91 ident: CR9 article-title: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa003034 contributor: fullname: Noda – volume: 49 start-page: 119 year: 2004 end-page: 133 ident: CR18 article-title: Progress in the therapy of small cell lung cancer publication-title: Crit Rev Oncol Hematol doi: 10.1016/S1040-8428(03)00118-5 contributor: fullname: Murren – volume: 27 start-page: 1401 year: 2009 end-page: 1404 ident: CR36 article-title: Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2008.20.2127 contributor: fullname: Chen – volume: 82 start-page: 2166 year: 1998 end-page: 2172 ident: CR28 article-title: A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19980601)82:11<2166::AID-CNCR11>3.0.CO;2-S contributor: fullname: Watanabe – volume: 6 start-page: 134 year: 2009 end-page: 135 ident: CR21 article-title: Should irinotecan or etoposide be used in combination with carboplatin for small cell lung cancer? publication-title: Nat Clin Pract Oncol doi: 10.1038/ncponc1324 contributor: fullname: Keilholz – volume: 49 start-page: 431 year: 1992 end-page: 435 ident: CR24 article-title: A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer publication-title: Oncology doi: 10.1159/000227087 contributor: fullname: Miyamoto – volume: 23 start-page: 21 year: 1996 end-page: 26 ident: CR6 article-title: CPT-11: an original spectrum of clinical activity publication-title: Semin Oncol contributor: fullname: Rothenberg – volume: 16 start-page: 31 year: 1976 end-page: 41 ident: CR13 article-title: Prediction of creatinine clearance from serum creatinine publication-title: Nephron doi: 10.1159/000180580 contributor: fullname: Gault – volume: 23 start-page: 3752 year: 2005 end-page: 3759 ident: CR25 article-title: Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.09.071 contributor: fullname: Niell – volume: 4 start-page: 1555 year: 2009 end-page: 1560 ident: CR41 article-title: Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3181bbc540 contributor: fullname: Spigel – volume: 7 start-page: 1748 year: 1989 end-page: 1756 ident: CR12 article-title: Carboplatin dosage: prospective evaluation of a simple formula based on renal function publication-title: J Clin Oncol contributor: fullname: Calvert – volume: 24 start-page: 2038 year: 2006 end-page: 2043 ident: CR22 article-title: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.8595 contributor: fullname: Hanna – volume: 5 start-page: 1574 year: 1987 end-page: 1578 ident: CR10 article-title: Carboplatin (CBDCA, JM-8) and VP-16–213 in previously untreated patients with small-cell lung cancer publication-title: J Clin Oncol contributor: fullname: Bishop – volume: 27 start-page: 2530 year: 2009 end-page: 2535 ident: CR23 article-title: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.20.1061 contributor: fullname: Lara – volume: 83 start-page: 855 year: 1991 end-page: 861 ident: CR20 article-title: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/83.12.855 contributor: fullname: Fukuoka – volume: 14 start-page: 193 year: 2000 end-page: 212 ident: CR32 article-title: Antineoplastic chemotherapy of the older cancer patient publication-title: Hematol Oncol Clin North Am doi: 10.1016/S0889-8588(05)70284-7 contributor: fullname: Corcoran – volume: 16 start-page: 1068 year: 1998 end-page: 1074 ident: CR8 article-title: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer publication-title: West Japan Lung Cancer Group. J Clin Oncol contributor: fullname: Kudoh – volume: 10 start-page: 1 year: 1989 ident: 9453_CR15 publication-title: Control Clin Trials doi: 10.1016/0197-2456(89)90015-9 contributor: fullname: R Simon – volume: 19 start-page: 3801 year: 2001 ident: 9453_CR42 publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.18.3801 contributor: fullname: ML Rothenberg – volume: 92 start-page: 205 year: 2000 ident: 9453_CR14 publication-title: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst contributor: fullname: P Therasse – volume: 27 start-page: 2530 year: 2009 ident: 9453_CR23 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.20.1061 contributor: fullname: PN Lara Jr – volume: 24 start-page: 2038 year: 2006 ident: 9453_CR22 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.8595 contributor: fullname: N Hanna – volume: 18 start-page: 309 year: 2004 ident: 9453_CR17 publication-title: Hematol Oncol Clin North Am doi: 10.1016/j.hoc.2003.12.008 contributor: fullname: BE Johnson – volume: 16 start-page: 1068 year: 1998 ident: 9453_CR8 publication-title: West Japan Lung Cancer Group. J Clin Oncol contributor: fullname: S Kudoh – volume: 6 start-page: 134 year: 2009 ident: 9453_CR21 publication-title: Nat Clin Pract Oncol doi: 10.1038/ncponc1324 contributor: fullname: A Schmittel – volume: 82 start-page: 2166 year: 1998 ident: 9453_CR28 publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19980601)82:11<2166::AID-CNCR11>3.0.CO;2-S contributor: fullname: H Okamoto – volume: 94 start-page: 1267 year: 2006 ident: 9453_CR30 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603079 contributor: fullname: A Kinoshita – volume: 12 start-page: 2022 year: 1994 ident: 9453_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.1994.12.10.2022 contributor: fullname: DC Ihde – volume: 5 start-page: 601 year: 1994 ident: 9453_CR11 publication-title: Ann Oncol doi: 10.1093/oxfordjournals.annonc.a058931 contributor: fullname: DV Skarlos – volume: 4 start-page: 1555 year: 2009 ident: 9453_CR41 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3181bbc540 contributor: fullname: DR Spigel – volume: 49 start-page: 431 year: 1992 ident: 9453_CR24 publication-title: Oncology doi: 10.1159/000227087 contributor: fullname: H Miyamoto – volume: 23 start-page: 3752 year: 2005 ident: 9453_CR25 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.09.071 contributor: fullname: HB Niell – volume: 1 start-page: 270 year: 2006 ident: 9453_CR2 publication-title: J Thorac Oncol doi: 10.1016/S1556-0864(15)31579-3 contributor: fullname: N Murray – volume: 14 start-page: 193 year: 2000 ident: 9453_CR32 publication-title: Hematol Oncol Clin North Am doi: 10.1016/S0889-8588(05)70284-7 contributor: fullname: L Balducci – volume: 5 start-page: 1574 year: 1987 ident: 9453_CR10 publication-title: J Clin Oncol doi: 10.1200/JCO.1987.5.10.1574 contributor: fullname: JF Bishop – volume: 346 start-page: 85 year: 2002 ident: 9453_CR9 publication-title: N Engl J Med doi: 10.1056/NEJMoa003034 contributor: fullname: K Noda – volume: 49 start-page: 119 year: 2004 ident: 9453_CR18 publication-title: Crit Rev Oncol Hematol doi: 10.1016/S1040-8428(03)00118-5 contributor: fullname: M Simon – volume: 94 start-page: 173 year: 2002 ident: 9453_CR33 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/94.3.173 contributor: fullname: CJ Langer – volume: 24 start-page: 2044 year: 2006 ident: 9453_CR27 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.03.3332 contributor: fullname: JR Eckardt – volume: 46 start-page: 516 year: 1969 ident: 9453_CR16 publication-title: Am J Med doi: 10.1016/0002-9343(69)90071-0 contributor: fullname: RA Green – volume: 24 start-page: 4539 year: 2006 ident: 9453_CR1 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.4859 contributor: fullname: R Govindan – volume: 27 start-page: 1401 year: 2009 ident: 9453_CR36 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.20.2127 contributor: fullname: G Chen – volume: 23 start-page: 2574 year: 2005 ident: 9453_CR43 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.81.908 contributor: fullname: MA Shah – volume: 16 start-page: 31 year: 1976 ident: 9453_CR13 publication-title: Nephron doi: 10.1159/000180580 contributor: fullname: DW Cockcroft – volume: 9 start-page: 172 year: 2009 ident: 9453_CR34 publication-title: Geriatr Gerontol Int doi: 10.1111/j.1447-0594.2009.00525.x contributor: fullname: J Li – volume: 26 start-page: 4261 year: 2008 ident: 9453_CR38 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.15.7545 contributor: fullname: A Hermes – volume: 83 start-page: 855 year: 1991 ident: 9453_CR20 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/83.12.855 contributor: fullname: M Fukuoka – volume: 14 start-page: 135 year: 1996 ident: 9453_CR3 publication-title: J Clin Oncol doi: 10.1200/JCO.1996.14.1.135 contributor: fullname: KM Rowland Jr – volume: 54 start-page: 365 year: 2006 ident: 9453_CR31 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2006.08.014 contributor: fullname: JH Sohn – volume: 27 start-page: abstr 8029 year: 2009 ident: 9453_CR39 publication-title: J Clin Oncol doi: 10.1200/jco.2009.27.15_suppl.8029 contributor: fullname: A Schmittel – volume: 23 start-page: 21 year: 1996 ident: 9453_CR6 publication-title: Semin Oncol contributor: fullname: ML Rothenberg – volume: 10 start-page: 1225 year: 1992 ident: 9453_CR7 publication-title: J Clin Oncol doi: 10.1200/JCO.1992.10.8.1225 contributor: fullname: N Masuda – volume: 53 start-page: 197 year: 2006 ident: 9453_CR35 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2006.05.004 contributor: fullname: H Okamoto – volume: 7 start-page: 1748 year: 1989 ident: 9453_CR12 publication-title: J Clin Oncol doi: 10.1200/JCO.1989.7.11.1748 contributor: fullname: AH Calvert – volume: 30 start-page: 23 year: 2000 ident: 9453_CR19 publication-title: Lung Cancer doi: 10.1016/S0169-5002(00)00127-6 contributor: fullname: C Mascaux – volume: 20 start-page: 879 year: 2008 ident: 9453_CR26 publication-title: Oncol Rep contributor: fullname: J Dimitroulis – volume: 2 start-page: 854 year: 2007 ident: 9453_CR40 publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e31814617b7 contributor: fullname: DR Spigel – volume: 10 start-page: 282 year: 1992 ident: 9453_CR4 publication-title: J Clin Oncol doi: 10.1200/JCO.1992.10.2.282 contributor: fullname: BJ Roth – volume: 17 start-page: 663 year: 2006 ident: 9453_CR37 publication-title: Ann Oncol doi: 10.1093/annonc/mdj137 contributor: fullname: A Schmittel – volume: 17 start-page: 2710 year: 1999 ident: 9453_CR29 publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.9.2710 contributor: fullname: RF DeVore |
SSID | ssj0021529 |
Score | 1.9708273 |
Snippet | This study was designed to evaluate the efficacy and safety of irinotecan in combination with carboplatin in previously untreated, extensive-disease small-cell... |
SourceID | proquest crossref pubmed springer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 342 |
SubjectTerms | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone Neoplasms - drug therapy Bone Neoplasms - secondary Brain Neoplasms - drug therapy Brain Neoplasms - secondary Camptothecin - administration & dosage Camptothecin - analogs & derivatives Carboplatin - administration & dosage Disease Progression Female Hematology Humans Internal Medicine Liver Neoplasms - drug therapy Liver Neoplasms - secondary Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medicine Medicine & Public Health Middle Aged Neoplasm Staging Oncology Original Paper Pathology Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - pathology Treatment Outcome |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV09T8MwED2VsrAgEF-hgDwwgawmdZw4E0KIUpBgolK3yHacKaSlTZf-eu7SpBWqQMoWJ3HOZ7_nu_MdwK0xVFval7j66QEPjfO5MsLxyCG-5daP8jqZzvtHNBqHbxM56cBLexaGwirbNbFeqLOpJRt5H2ElUolMor42ZASwVf9h9s2pfBS5WZtaGnuwHwyQVaBix5PtzgtBKql3XjLmiPgb92Z9ho5qiHPyCSehFHz1G6B2WOeOx7QGouERHDYMkj2uh_wYOq48gfErNqaMC7pks2K5YFbPzXRGgW4lw6tJn7pgZHdlteWb4tZ5459hiy9dFJys-KzA6Y-PozLMT2E8fP58GvGmYgK3IvYrnvs208kgz4hFmcQ4JFdWOz9xQaai0Ko4RM0RLo9sjjikg1xGsZ9RihyRJyoUZ9Atp6W7ACasDJQTVmSZDC2iFqVAMtoMNHI-pYwHd62Y0tk6MUa6TYFMMk1RpinJNF150GsFmTZzZJFuRtQDtrmLyk3_qks3XdZNcD-GnNaD87X4N99C4oIdlsqD-3Y8tq_-syOX_3akBwdrkzGFmF1Bt5ov3TVyjsrc1Pr0A6bc0-I priority: 102 providerName: ProQuest |
Title | Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer |
URI | https://link.springer.com/article/10.1007/s12032-010-9453-z https://www.ncbi.nlm.nih.gov/pubmed/20198458 https://www.proquest.com/docview/853689596/abstract/ https://search.proquest.com/docview/853996800 |
Volume | 28 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV07T8MwED4VKiEWxJvwqDwwgYzSOE6csaDyFAghKpUpsh1noaRVHwu_nrs0TYWAASlShtiOcz77--7OOQOcGkNnS_sSVz8d8NA4nysjHI8c4ltu_Sgvk-k8PkW3vfC-L_sNCGrXRfF-sYhIlgv18l83OuubU-w2CaXgnyvQJO5AmtwLOrWRhXiUlEaWjDmCex3J_K2J71j0g2D-CI6WmHO9CRsVWWSd-ehuQcMV27D2WIXDd6B3h_Uoz4Iu2GgwmzCrx2Y4ou1tBcOrSpo6YeRtZaW_m3ar8yoqwyYfejDg5LtnA5z0WB1VYLwLvevu69Utr85J4FbE_pTnvs10EuQZcSeTGIdisdr5iWtnKgqtikPUF-HyyOaIPrqdyyj2M0qMI_JEhWIPVoth4Q6ACSvbygkrskyGFrGKEh8ZbQKNTE8p48HZQmLpaJ4OI10mPibxpijelMSbfnpwtJBpWs2MSYr0IFKJTCIPWP0UVZq-VRduOCuLoBWGTNaD_flI1O9CuoIdlsqD88XQLJv-syOH_yp9BOtzxzFtNDuG1el45k6QeUxNC1biftyCZufm7aGL98vu0_NLq1TAL41X1E0 |
link.rule.ids | 315,786,790,12083,21416,27957,27958,31754,31755,33779,33780,41116,41558,42185,42627,43345,43840,52146,52269,74102,74659 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV07T8MwED5BO8CCQLxCeXhgAlmkdZw6EwIEanlUCFGJLbIdZyppadqFX89d6gYhBFK2vJzz2d93j9wBnBpDvaVDibuf7vDIuJArIxyPHeJbbsM4r4rpPA3i3jC6f5NvPjen9GmVyz2x2qizsSUf-QXCSqwSmcSXkw9OTaMouOo7aKxCMxJoqTSgeX07eH6pLS4Ep6SyuGSXI9LXYc3q3znqHc4pFpxEUvDPn8D0i23-ipRWAHS3CRueObKrxVRvwYortmHYx4up0oIu2GQ0L5nVUzOeUIJbwfDwZVNLRv5WVnm8KV-d-7gMK9_1aMTJe89GuOzxdlSC6Q4M725fb3rcd0rgVnTDGc9Dm-mkk2fEnkxiHJIqq12YuHam4siqboQaI1we2xzxR7dzGXfDjErjiDxRkdiFRjEu3D4wYWVbOWFFlsnIIlpR6SOjTUcj11PKBHC2FFM6WRTESL9LH5NMU5RpSjJNPwNoLQWZ-rVRpvVMBsDqs6jU9K26cON5dQnaYchlA9hbiL9-FxIWHLBUAZwv5-P70X8O5ODfgZzAWu_16TF97A8eWrC-cBtTmtkhNGbTuTtC3jEzx167vgDt29R7 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLZ4SIgLAvEqzxw4gSK6pWnTE0LAxFscmLRblaTJaXRj3S78euwu24QQSL01bVPH9ffFdm2AM2Oot3Qs0frpNk-Mi7kywvHUIb55G6e-Kabz8pred5PHnuyFkkJ1SKuc2cTGUJcDSz7yS4SVVOUyTy99yIp4u-1cDT85NZCiQGvoprEMqwiSMTUzyHqLvRfCVN7svWTGEfPnAc7mLzrqIs4pKpwnUvCvnxD1i3f-ipk2UNTZhI3AIdn1dNG3YMlV29B9wMFUc0FXbNif1MzqkRkMKdWtYniEAqo1I88ra3zflLnOQ4SG1R-63-fkx2d9NAB4OarDaAe6nbv3m3seeiZwK7J4zH1sS523fUk8yuTGIb2y2sW5a5UqTazKEtQd4XxqPSKRbnmZZnFJRXKEz1UidmGlGlRuH5iwsqWcsKIsZWIRt6gIktGmrZH1KWUiOJ-JqRhOS2MUiyLIJNMCZVqQTIuvCA5ngizCV1IX8zWNgM3PonrTu-rKDSbNENyRIauNYG8q_vmzkLrghKWK4GK2Hotb_zmRg38ncgprqFbF88Pr0yGsT_3HlG92BCvj0cQdIwEZm5NGtb4BI3HXQQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Irinotecan+plus+carboplatin+in+patients+with+extensive-disease+small-cell+lung+cancer&rft.jtitle=Medical+oncology+%28Northwood%2C+London%2C+England%29&rft.au=Kim%2C+Young+Saing&rft.au=Park%2C+Se+Hoon&rft.au=Kyung%2C+Sun+Young&rft.au=Sym%2C+Sun+Jin&rft.date=2011-03-01&rft.issn=1357-0560&rft.eissn=1559-131X&rft.volume=28&rft.issue=1&rft.spage=342&rft.epage=350&rft_id=info:doi/10.1007%2Fs12032-010-9453-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s12032_010_9453_z |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1357-0560&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1357-0560&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1357-0560&client=summon |